Evogene Ltd. (EVGN)
NCM · Healthcare · Biotechnology
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About Evogene Ltd.
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the development and commercialization of castor bean seeds for industrial uses. In addition, the company medical cannabis products. It has a collaboration with LMU University Hospital Munich to develop novel therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD). The company was incorporated in 1999 and is headquartered in Rehovot, Israel.
Quarterly Financials
| Metric | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 2.4M | 884K | 312K | 314K |
| Gross Profit | 830K | 748K | 155K | -2.0M |
| Operating Income | -4.1M | -3.1M | -2.7M | -5.2M |
| Net Income | -2.6M | -4.5M | 3.9M | -5.3M |
| Diluted EPS | $-0.38 | $-0.62 | $0.44 | $-0.61 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 1.7M | 3.0M | 5.6M | 3.9M |
| Gross Profit | 766K | 1.5M | 3.2M | -241K |
| Operating Income | -26.9M | -22.2M | -18.8M | -14.0M |
| Net Income | -26.6M | -23.9M | -16.5M | -8.5M |
| Diluted EPS | $-6.50 | $-5.20 | $-2.89 | $-1.08 |